tiprankstipranks
Trending News
More News >

Argenica Therapeutics Announces Cessation of Securities

Story Highlights
Argenica Therapeutics Announces Cessation of Securities

Don’t Miss TipRanks’ Half-Year Sale

Argenica Therapeutics Ltd ( (AU:AGN) ) just unveiled an announcement.

Argenica Therapeutics Ltd has announced the cessation of 113,478 securities, specifically options that expired on July 6, 2025, with an exercise price of $0.65. This cancellation, agreed upon by the entity and the holder, may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategy.

The most recent analyst rating on (AU:AGN) stock is a Buy with a A$1.14 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.

More about Argenica Therapeutics Ltd

Argenica Therapeutics Ltd operates in the biotechnology industry, focusing on the development of therapeutic solutions. The company is engaged in creating innovative treatments aimed at addressing neurological conditions, with a market focus on advancing medical therapies.

Average Trading Volume: 94,515

Technical Sentiment Signal: Buy

For detailed information about AGN stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1